Vaccine dilemma: To take or not to take Covaxin
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
A Science and Technology Blog
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
Scientists, manufacturers and drug regulators have been speeding up the timelines to develop, test and approve vaccines for emergency use. Three safe and efficacious vaccines from Pfizer, Moderna and AstraZeneca…
With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.
Unlike in other groups, national databases of people with comorbidities are not available. However, though not comprehensive, since 2010, State governments have been conducting population-based district level screening to detect…
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of age and those aged below 50 years but with co-morbidities…
The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s Bharat Biotech underlines the regulator’s priorities even for emergency use…
Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to secure a nod from any of the regulatory agencies despite…
But the government’s idea of vaccinating a “critical mass of people” for the purpose of breaking the virus transmission chain is riddled with problems. Unlike the mRNA vaccines from Pfizer…